Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Immunol. 2018 Feb 23;200(7):2327–2340. doi: 10.4049/jimmunol.1701391

Figure 4. Identification of citrullinated LL-37.

Figure 4

(A) Western Blot analysis of native and fully-citrullinated LL-37 using antibodies against native LL-37 (LL-37 ab) and anti-modified citrulline proteins (AMC ab). The red dashed line showed the section where the membrane was cut to allow the incubation of different antibodies as described previously. (B) Western Blot verification of the recognition of differentially citrullinated forms of LL-37 by antibodies against native LL-37. (C) MSMS spectra of LL-37 N-terminal tryptic peptide (LLGDFFR), confirming the presence of mature LL-3. (D) The half-life of native LL-37 and its variably citrullinated forms in NETs, healthy and inflamed sera (RA serum) and synovial fluid of rheumatoid arthritis patients. Unpaired t-test was used to calculate the p values between groups (*=p<0.05).